Was looking at a stock today IPD. Today the National...

Was looking at a stock today IPD.
Today the National Comprehensive Cancer Network recommended Impedimed product SOZO for testing lymphoedma. ImpediMed has the only FDA-cleared BIS technology for the assessment of lymphoedema.

12.30 am tired and grumpy so not fully researched but want to get this post out to get some curiosity and thoughts happening.

Was reading Leeking post and what jumped out at me was the comment referring to the pulse possible numbers.
"Typically, the market sees growth and potential and values such companies at a much higher multiple than that."
https://hotcopper.com.au/threads/general-forum.5903010/page-868?post_id=66190399

Looking at IPD it seems that the market was valuing IPD at those much higher multiples.

IPD run of a SAAS model.
Before todays announcement IPD market cap was 223 million with half year ARR annual recurring revenue of 8 million with 90% gross margin on ARR revenue,
10 million loss for the half and 26 million in the bank and close to 9 month low. 100% move today.
A poster ON IPD thread wrote IPD does not get paid by the number of SOZO tests, only by the monthly license fee for each SOZO unit.
An increase in the number of SOZO tests allows IPD increase the license fees. Table below shows hospitals reimbursed 6.58M from 47000 tests, From the 6.58M they pay IPD 2.7M and keep 3.8M in the Hospital pocket. I expect some hospitals do very well from this deal while others may only be break even or lose money if the unit is in a low turnover facility.

I think once the pulse receives FDA clearance the market may hopefully rerate CDX .
Most likely will see some profit taking but those with a vision may be holding or taking a position.
An announcement after FDA clearance that someone will take 30,000 units or something similair would get the market valuing CDX at much higher multiples.